Andromeda Surgical vs Andson Biotech
Side-by-side comparison of AI visibility scores, market position, and capabilities
Surgical robotics company achieving world's first robotic-assisted HoLEP for prostate treatment; YC-backed targeting $10B+ urology market with Richard Wolf and Quanta System partnerships.
About
Andromeda Surgical is a surgical robotics company developing autonomous robots for urological procedures — specifically targeting the HoLEP (Holmium Laser Enucleation of the Prostate) procedure used to treat benign prostatic hyperplasia (BPH, enlarged prostate), a condition affecting 50%+ of men over 50. Founded in 2023 by CEO Nick Damiano and CTO Kartik Tiwari and a Y Combinator S23 graduate, Andromeda raised $500,000 in seed funding from CoreNest and YC, and achieved the world's first robotic-assisted HoLEP procedure in December 2024 — a significant clinical milestone.\n\nAndromeda's surgical robot assists urologists performing HoLEP procedures by providing precise laser energy delivery and tissue manipulation, targeting the improvement in procedural consistency and outcome reproducibility that robotic assistance provides across varying surgeon skill levels. HoLEP is considered the gold standard treatment for BPH but has a steep learning curve — it requires 30-50+ procedures to achieve proficiency, limiting its adoption to high-volume academic medical centers. Andromeda's robotic assistance aims to make HoLEP accessible at community hospitals by reducing the expertise barrier.\n\nIn 2025, Andromeda competes in the surgical robotics market with Intuitive Surgical (da Vinci for soft tissue surgery), GYRUS Medical (urological instruments), and emerging robotic surgery startups targeting different procedural niches for surgical automation. The global urology surgery robotics market represents a $3+ billion opportunity, with the broader HoLEP addressable market estimated at $10+ billion. Strategic partnerships with Richard Wolf (endoscopy equipment) and Quanta System (laser platforms) provide Andromeda with established distribution channels and clinical credibility. The 2025 strategy focuses on additional clinical procedures to build the safety evidence required for FDA clearance, expanding from the first-in-human milestone toward a pivotal trial for regulatory submission.
Mass spectrometry sample prep and data science platform delivering 100x productivity for biopharma protein analysis; $9.1M from Merck Digital Sciences Studio, NIH, and YC at $1.8M revenue.
About
Andson Biotech is an Atlanta-based healthcare technology company providing mass spectrometry solutions for biopharma and biomanufacturing — offering the DynaCHIP hardware system (a novel mass spectrometry sample preparation platform) and DynaMARK data science module that together deliver up to 100x productivity improvements in protein and biomolecule analysis workflows compared to conventional mass spectrometry setups. Backed by Y Combinator, Merck Digital Sciences Studio, and NIH with $9.1 million raised, Andson achieved $1.8 million in revenue as of December 2024.
AI Visibility Head-to-Head
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.